Aptuit, Inc. Company Profile

News Articles [ 29 Associated News Articles listed on BioPortfolio]

Aptuit Drug Discovery & Development Center In Verona, Italy Hits 100th Client Milestone

GREENWICH, Conn., Nov. 8, 2012 /- Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, announced that the number of clients placing work at The Aptuit Center for Drug Discovery &a...

Aptuit, Aegerion enter supply deal for orphan drug lomitapide

Aegerion has entered into a long-term deal with Aptuit for supply of commercial quantities of its active pharmaceutical ingredient (API) lomitapide.

Aptuit, GSK extend strategic drug development deal

Aptuit and GlaxoSmithKline (GSK) have extended strategic drug development partnership to carry out work at the Aptuit Center for Drug Discovery & Development in Verona, Italy.

Aptuit and GSK Extend Strategic Partnership

GREENWICH, Conn., Nov. 13, 2012 /PRNewswire/ -- Aptuit LLC announced that the company has reached an agreement on a multiyear extension of its strategic partnership with GlaxoSmithKline (GSK) for...

Former Aptuit Employee Found Guilty Of Data Scam

A former employee of the Aptuit clinical research organization was found guilty of altering pre-clinical trial data that was used to support applications to perform clinical trials, according to the U...

Aptuit and Aegerion Sign Commercial API Supply Agreement

GREENWICH, Conn., Jan. 8, 2013 /PRNewswire/ -- Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, announced that Aptuit and Aegerion Pharmaceuticals, Cambridge, Massachusetts, h...

Aptuit, GlaxoSmithKline deal

Aptuit OffersBiodistribution Studies

Expands preclinical research services

Drugs and Medications [0 Results]

None

PubMed Articles [ 10 Associated PubMed Articles listed on BioPortfolio]

Recent advances in the development of dopamine d(3) receptor antagonists: a medicinal chemistry perspective.

Dopamine (DA) D(3) receptor antagonism might play a significant role in different therapeutic areas. A high number of preclinical studies on DA D(3) receptor antagonists have shown efficacy in animal...

Towards the discovery of new hypnotic agents: synthesis and preliminary pharmacological evaluation of a novel class of dibenzoa,dcycloheptene derivatives.

Contribution of rat intestinal metabolism to the xenobiotics clearance.

Michaelis-Menten constants K (m) and V (max) values were determined by product formation and substrate depletion at several substrate concentrations of 4-methylumbelliferone using rat intestinal micro...

2-Methyl-3-furanyl-4H-1,2,4-triazol-3-ylthioamides: a new class of selective orexin 2 antagonists.

A new class of selective orexin 2 antagonist was identified among commercial products. Initial SAR was obtained using commercial derivatives only prior to starting ad hoc medicinal chemistry activitie...

Exploration of the amine terminus in a novel series of 1,2,4-Triazolo-3-yl-azabicyclo3.1.0hexanes as selective dopamine D3 receptor antagonists.

A novel series of 1,2,4-triazol-3-yl-azabicyclo[3.1.0]hexanes with high affinity and selectivity for the DA D(3) receptor and excellent pharmacokinetic profiles was recently reported. We also recently...

Clinical Trials [0 Results]

None

Companies [ 4 Associated Companies listed on BioPortfolio]

Aptuit, Inc.

Aptuit, Inc. is a global pharmaceutical services company focused on delivering contract development and manufacturing services and streamlining the drug development process for bi...

Aptuit Informatics

Aptuit Informatics (formerly InfoPro Solutions) was acquired by Aptuit Inc. and is one of five business lines operating under the Aptuit umbrella. Download the Aptuit Corporate Fact Sheet (PDF). Aptui...

Aptuit (Allendale) Inc

Aptuit, Inc. (formerly Global Pharmaceutical Development, Inc.) is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovato...

Iroko Pharmaceuticals, LLC and Aptuit Inc.